Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 07, 2009 6:38 PM

Last Updated: 03/30/2009 - Able2Act


Fact Sheet for Elan Corporation, plc

Industry: Pharmaceuticals
Country: USA
Contact: Elan Corporation plc,
Treasury Building,
Lower Grand Canal Street,
Dublin 2,
Ireland
Management:
  • G. Kelly Martin ; Carlos Paya ; Menghis Bairu ; Chris Burns ; Nigel Clerkin ; Richard T. Collier ; Shane Cooke ; William Daniel ; Allison Hulme ; Karen Kim : Kathleen Martorano ; Johannes Roebers ; Dale Schenk ; Steven Slaughter ; Mary Stutts ; Ted Yednock
Homepage: http://www.elan.com
Comments:
  • Elan Corporation, plc is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain.

    On June 5, 2006, Elan and Biogen Idec announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for the reintroduction of TYSABRI® (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the frequency of clinical relapses.

    The FDA granted approval for re-introduction based on the review of TYSABRI clinical trial data; revised labeling with enhanced safety warnings; and a risk management plan (TOUCH Prescribing Program) designed to inform physicians and patients of the benefits and risks of TYSABRI treatment and minimize potential risk of progressive multifocal leukoencephalopathy (PML). Because of the increased risk of PML, TYSABRI monotherapy is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate MS therapies.

    TYSABRI became commercially available in the US in July 2006. Under the TOUCH Prescribing Program, only prescribers, infusion centers, and pharmacies associated with infusion centers registered in the TOUCH program are able to prescribe, infuse or distribute TYSABRI. Elan has contracted with a single distributor, ICS, a division of AmerisourceBergen Specialty Group, and 12 specialty pharmacies: Caremark, CuraScript, PharmaCare, PrecisionRx Specialty Solutions, Medmark, BioScrip, McKesson Specialty, Option Care, Cigna Tel-Drug Specialty Pharmacy, Aetna Specialty Pharmacy, Prescription Solutions, and Accredo NovaFactor. ICS and the 12 specialty pharmacies have been trained on the TOUCH Prescribing Program and are obligated to follow the requirements of the program in order to purchase and distribute TYSABRI to authorized infusion sites and central pharmacies.

    On June 29, 2006, Elan and Biogen Idec announced that they received approval from the European Commission to market TYSABRI® (natalizumab) as a treatment for relapsing remitting multiple sclerosis (MS) to delay the progression of disability and reduce the frequency of relapses. TYSABRI is indicated as a single disease modifying therapy in highly active relapsing remitting MS for patients with high disease activity despite treatment with a beta-interferon or in patients with rapidly evolving severe relapsing remitting MS.

    TYSABRI was launched in Germany, Ireland, U.K. and Sweden in July 2006, and will be launched in other EU countries over the next 12 months.

    On December 28, 2004, the U.S. Food and Drug Administration (FDA) approved PRIALT® (ziconotide intrathecal infusion) for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or IT morphine. PRIALT is approved for use only in the Medtronic SynchroMed® EL, SynchroMed® II Infusion System and CADD-Micro® ambulatory infusion pump.

    On February 22, 2005, the European Commission granted Elan marketing approval for PRIALT? (ziconotide) for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia.

    Elan's focus on improving the health of patients suffering from chronic and debilitating conditions is exemplified by its breakthrough research program in Alzheimer's disease, where it has developed three novel therapeutic approaches:

    Immunotherapy In collaboration with Wyeth, this approach targets the clearance of beta-amyloid, the peptide responsible for the build-up of amyloid plaques in the brain

    Beta secretase inhibitors Targets a distinct enzyme associated with the production of beta-amyloid

    Gamma secretase inhibitors Targets a distinct enzyme associated with the production of beta-amyloid
    In neurology, Elan is focused on building upon its breakthrough research and extensive experience in the area of neuropathology-based disorders. In addition to Alzheimer?s disease, Elan is also studying other neurodegenerative diseases, such as Parkinson's disease.

    In autoimmune diseases, Elan?s primary emphasis is studying and developing ways to provide disease-modifying therapies for a wide range of diseases.

    In severe pain, Elan?s research efforts focus on inflammatory and neuropathic pain.

    For more information about Elan?s research and development program, please click here.

    Elan?s marketed products in the the United States include:

    PRIALT® (ziconotide intrathecal infusion)
    AZACTAM® (aztreonam for injection, USP)
    MAXIPIME® (cefepime hydrochloride) for Injection
    For more information about Elan?s products and pipeline, please click here.

    Elan?s Manufacturing business unit develops and manufactures pharmaceutical products for Elan and other customers, providing innovative drug optimization technologies, advanced manufacturing capabilities and global supply chain management services.


    Key Facts
    Locations:
    Athlone, Ireland
    Bermuda
    Dublin, Ireland (headquarters)
    Gainesville, Georgia
    King of Prussia, Pennsylvania
    South San Francisco, California
    Tokyo, Japan
    Employees
    Approximately 1,600 worldwide
Compilation by Silobreaker
Although Silobreaker has relied on what it regards as reliable sources while compiling the content herein, Silobreaker cannot guarantee the accuracy, completeness, integrity or quality of such content and no responsibility is accepted by Silobreaker in respect of such content. Readers must determine for themselves what reliance they should place on the compiled content herein.

Related Stories

First Reported 11/06/2009 - Updated 3 hours ago - 6 Documents (in Health)
FDA Warns Against Marketing Illegal Flavored Cigarettes
The U.S. Food and Drug Administration is enforcing the flavored cigarette ban provision of the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) by issuing several warning letters to companies continuing to sell illegal flavored ... [Red Orbit - 3 hours ago]
First Reported 11/02/2009 - Updated 11/02/2009 - 2 Documents (in Health)
Food and Drug Administration - Click to view 360-page
Food and Drug Administration
FDA won't accept Merck's application for new drug
Treasury prices tumbled Monday, pushing their yields higher, as stronger-than-expected reports on manufacturing and housing allay some concerns about the strength of the U.S. economic ... ... [SignOn San Diego - 11/02/2009]
First Reported 10/23/2009 - Updated 10/24/2009 - 13 Documents (in Health)
Elan shares fall by 20pc as drug-linked disease cases rise
Shares in Elan plunged 20pc to ?3.42 in Dublin yesterday after its multiple sclerosis treatment Tysabri was linked to over 20 cases of a potentially fatal brain disease and the European drug watchdog said it was reviewing its use. Elan finished at ?3.42 ... [Irish Independent - 10/24/2009]
First Reported 10/20/2009 - Updated 10/21/2009 - 8 Documents
Biogen sinks on new worry over Tysabri
Biogen Idec has reported third-quarter earnings that topped expectations, but concern over the future of its multiple sclerosis drug Tysabri sent its shares down more than 2 percent.Revenue from sales of Tysabri rose 21 percent to USD 207 million in the ... [Ireland Business World - 10/21/2009]
First Reported 10/21/2009 - Updated 10/22/2009 - 5 Documents (in Biology)
Johnson & Johnson - Click to view image in its original context
Johnson & Johnson
Elan focuses on boosting MS drug sales after selling stake to J&J
Kelly Martin, chief executive of Elan, said the Irish drugs group would focus on increasing sales of its multiple sclerosis drug Tysabri, following the sale of a stake... ... [FT.com - Health - 10/22/2009]
First Reported 10/15/2009 - Updated 10/16/2009 - 10 Documents (in Health)
Acorda gets positive FDA review for MS drug
Acorda Therapeutics said the Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs (PCNSD) Advisory Committee has approved its multiple sclerosis (MS) drug after it demonstrated substantial evidence of effectiveness as a treatment ... [Bio Spectrum Asia - 10/16/2009]
First Reported 10/14/2009 - Updated 10/14/2009 - 3 Documents
Elan Corporation, plc - Click to view image in its original context
Elan Corporation, plc
Zacks Analyst Blog Highlights: American International Group, Morgan Stanley, Elan Corporation,...
BusinessWire - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ... [Forbes.com - 10/14/2009]
First Reported 10/14/2009 - Updated 10/15/2009 - 6 Documents (in Health)
FDA Staffers Express Concern Over MS Drug Fampridine SR
Acorda Therapeutics' multiple sclerosis (MS) treatment Amaya 'has a very limited effect,' according to documents released on the FDA Web site ahead of an advisory panel meeting on Oct. 14. Acorda has conducted several trials on the drug, one of which ... [AAPS Pharmceutica - 10/15/2009]
First Reported 10/09/2009 - Updated 10/10/2009 - 5 Documents (in Health)
Acorda Staggers on FDA Word: MS Drug's Walk Data Below Par
Second Look at Trial Data By Donna Young Washington EditorAcorda Therapeutics Inc.'s stock plunged 21.4 percent after FDA drug reviewers raised concerns in briefing documents about the efficacy of Amaya (fampridine sustained-release) in improving the ... [BioWorld - 10/10/2009]
First Reported 10/15/2009 - Updated 10/16/2009 - 4 Documents (in Health)
FDA Warns of Online H1N1 Drugs
You just knew this was coming. The Food and Drug Administration (FDA) is warning Americans to beware of buying drugs claiming to treat the H1N1 flu virus, otherwise known as Swine Flu, from online vendors.The FDA issued its warning after investigators ... [About - 10/16/2009]
First Reported 10/23/2009 - Updated 10/23/2009 - 1 Documents (in Medicine)
Phony Online Flu Cures Draw FDA Ire
The US Food and Drug Administration (FDA) is monitoring the online marketing and sale of products that claim to diagnose, prevent, treat or cure the H1N1 influenza virus - and in at least one high-profile case - is ordering the well-established brand, ... [MarketingVOX - 10/23/2009]
First Reported 10/24/2009 - Updated 10/24/2009 - 1 Documents (in Health)
FDA is back in business
Paying attention to thinking about consumers again? What a crazy idea!The Smart Choices nutrition labeling program, created voluntarily by nine large U.S. manufacturers, is halting after federal regulators said such systems could mislead consumers, officials ... [AMERICAblog News| A great nation deserves the t ... - 10/24/2009]
In Focus
Network

Blogs

sort by: Date | Relevance
Elan Corporation: Shares Seem Undervalued [Biotech Sector and Stocks Analysis from Seeking ... - 07/10/2009]
Elan Corporation (ELN) About Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing ...
J&J lowers price of Elan stake [The Deal.com - 09/15/2009]
Irish drugmaker Elan Corp. plc has revised its agreement with healthcare giant Johnson & Johnson and will get $885 million for an 18.4% stake in the company -- $115 ...
Elan (ELN) drops on Tysabri troubles [BloggingStocks - 06/29/2009]
Filed under: Major movement, Bad news, Options, Technical AnalysisElan Corp (NYSE: ELN - option chain) stock is falling today after Biogen (NASDAQ: BIIB) reported ...
J&J and Elan Cut Deal Price to Resolve Biog... [DealBook - 09/15/2009]
Johnson & Johnson has cut the amount it will pay for its 18.4 percent stake in Irish drugmaker Elan Corp by $115 million to $885 million, Elan confirmed Monday. ...
Elan: Yet another deal rumor -- Bristol eyeing ... [BloggingStocks - 06/01/2009]
Filed under: Deals, Rumors, Bristol-Myers Squibb (BMY)If you've been following Elan Corp. (NYSE: ELN) lately, you've probably come to take any story of a deal, takeover, ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
multiple sclerosis [Mefeedia Video Tag : medicine - 04/01/2009]
multiple sclerosis [Mefeedia Video Tag : medicine - 04/03/2009]
FDA to regulate tobacco [Reuters Video: Top News - 06/12/2009]
Did black box warnings on antidepressants have ... [Slate Magazine - 09/15/2009]
Anti-Medicine Man: the FDA and Medical Progress... [Mefeedia Video Tag : medicine - 06/02/2009]
1 2 3 4 5

  •  
  •  
  •